Cetrorelix (CAS 120287-85-6) is a high-purity GnRH antagonist peptide API, a potent inhibitor of gonadotropin secretion. With a precise 10-amino acid peptide structure, it acts by competitively binding to GnRH receptors in the pituitary gland, thereby blocking the effects of endogenous GnRH. This rapid inhibition leads to a significant reduction in LH and FSH levels, and subsequently, a decrease in testosterone and estradiol production.
Produced under strict GMP standards, this API ensures consistent purity (≥98%) and biological activity, making it ideal for pharmaceutical formulation. It is widely applied in the development of drugs for assisted reproductive technology (ART), such as in vitro fertilization (IVF), to prevent premature luteinizing hormone (LH) surges and ensure the timely maturation of follicles. It is also used in the treatment of prostate cancer and endometriosis.
Its unique mechanism of action provides precise control over gonadotropin levels, making it a preferred choice for clinical use. Cetrorelix delivers reliable therapeutic benefits with a favorable safety profile, catering to the needs of pharmaceutical manufacturers and research institutions in the field of reproductive medicine.
